Stocklytics Platform
Asset logo for symbol NAMSW
NewAmsterdam Pharma Company N.V.
NAMSW3
$6.970.00%$0.00
Asset logo for symbol NAMSW
NAMSW3

$6.97

0.00%

Income Statement (NAMSW)

itemJun 2024Mar 2024Jun 2023Mar 2023Dec 2022
EBIT-$60.09M-$55.49M-$42.58M-$35.52M$22.37M
EBITDA-$60.07M-$55.48M-$42.55M-$35.51M$22.36M
gross Profit$2.27M$1.38M$1.76M$8.62M$97.50M
NET Income-$39.00M-$93.76M-$39.59M-$42.01M$20.36M
total Revenue$2.27M$1.40M$1.76M$8.62M$97.50M

Balance Sheet (NAMSW)

itemJun 2024Mar 2024Dec 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$430.14M-$445.87M-$340.39M-$383.40M-
stockholders Equity$387.43M$381.65M$288.39M$422.26M-
total Assets$446.69M$452.69M$347.09M$471.09M-
total Debt$562.00K$39.85K$60.00K$87.00K-
total Liabilities$59.25M$71.04M$58.70M$48.83M-

Cash Flow (NAMSW)

itemJun 2024Mar 2024Dec 2023Jun 2023Mar 2023
financing Cash Flow$4.65M$198.18M-$6.32M$2.39M
free Cash Flow-$54.18M-$54.98M--$36.44M-$31.87M
investing Cash Flow-----
operating Cash Flow-$53.97M-$54.60M--$36.45M-$31.86M

NewAmsterdam Pharma Company N.V. (NAMSW) Financials

The income statement of NewAmsterdam Pharma Company N.V. (NAMSW) provides a summary of the company's financial performance over a given period. It includes information on revenue, expenses, and net income. This statement is crucial for evaluating the profitability of the company.
EBIT (Earnings Before Interest and Taxes) is a measure that indicates a company's operating profitability. It excludes interest and taxes to focus solely on the core earnings generated from operations. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a similar metric that further excludes depreciation and amortization expenses.
Gross profit represents the revenue remaining after deducting the cost of goods sold. It reflects the profitability of the company's products or services. Net income from stockholders accounts for any dividends paid out to stockholders. It is calculated by subtracting dividends from the company's net income.
Total revenue refers to the overall income generated by the company from all sources. It includes revenue from the sale of products or services, as well as any other sources of income. The balance sheet provides a snapshot of the company's financial position at a specific point in time. It shows the company's assets, liabilities, and stockholders' equity.
Cash equivalents refer to highly liquid assets that can be easily converted into cash. They are typically short-term investments with a maturity of three months or less. Net debt is the difference between a company's total debt and its cash and cash equivalents. It gives an indication of the company's financial leverage.
Stockholders' equity represents the residual interest in the assets of the company after deducting liabilities. It is the value of the company that belongs to its shareholders. Total assets include all of the company's resources, including cash, property, inventory, and intangible assets. Total debt represents all of the company's obligations to repay borrowed money.
Total liabilities encompass all of the company's debts and obligations. This includes both short-term and long-term liabilities. Cash flow refers to the movement of cash in and out of the company. It provides insights into the company's ability to generate cash.
Financing cash flow represents the cash inflows and outflows related to financing activities, such as issuing or repurchasing stock and paying dividends. Free cash flow is the amount of cash generated by the company after accounting for capital expenditures and working capital needs.
Investing cash flow represents the cash inflows and outflows related to investment activities, such as acquiring or disposing of assets. Operating cash flow represents the cash generated from the company's core operations, excluding financing and investing activities.
add NewAmsterdam Pharma Company N.V. to watchlist

Keep an eye on NewAmsterdam Pharma Company N.V.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media